INDIUM IN 111 OXYQUINOLINE Drug Patent Profile
Which patents cover Indium In 111 Oxyquinoline, and when can generic versions of Indium In 111 Oxyquinoline launch?
Indium In 111 Oxyquinoline is a drug marketed by Bwxt Itg and Ge Healthcare and is included in two NDAs.
The generic ingredient in INDIUM IN 111 OXYQUINOLINE is indium in-111 oxyquinoline. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the indium in-111 oxyquinoline profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for INDIUM IN 111 OXYQUINOLINE?
- What are the global sales for INDIUM IN 111 OXYQUINOLINE?
- What is Average Wholesale Price for INDIUM IN 111 OXYQUINOLINE?
Summary for INDIUM IN 111 OXYQUINOLINE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Patent Applications: | 39 |
| What excipients (inactive ingredients) are in INDIUM IN 111 OXYQUINOLINE? | INDIUM IN 111 OXYQUINOLINE excipients list |
| DailyMed Link: | INDIUM IN 111 OXYQUINOLINE at DailyMed |
US Patents and Regulatory Information for INDIUM IN 111 OXYQUINOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bwxt Itg | INDIUM IN 111 OXYQUINOLINE | indium in-111 oxyquinoline | INJECTABLE;INJECTION | 202586-001 | Jul 25, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Ge Healthcare | INDIUM IN 111 OXYQUINOLINE | indium in-111 oxyquinoline | INJECTABLE;INJECTION | 019044-001 | Dec 24, 1985 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INDIUM IN 111 OXYQUINOLINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | INDIUM IN 111 OXYQUINOLINE | indium in-111 oxyquinoline | INJECTABLE;INJECTION | 019044-001 | Dec 24, 1985 | 4,335,095 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INDIUM IN 111 OXYQUINOLINE
See the table below for patents covering INDIUM IN 111 OXYQUINOLINE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 3062496 | ⤷ Start Trial | |
| European Patent Office | 0017355 | INDIUM-111 OXINE COMPLEX COMPOSITION | ⤷ Start Trial |
| Japan | S55129229 | INDIUMM1111OXINE COMPLEX COMPOSITION | ⤷ Start Trial |
| Japan | S5914452 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch